subscribeSubscribe
US FDA approves Regeneron-Sanofi’s Kevzara to treat polymyalgia rheumatica

US FDA approves Regeneron-Sanofi’s Kevzara to treat polymyalgia rheumatica
PHARMACEUTICAL TECHNOLOGY
02 Mar 2023
Share Share
Kevzara Approved by FDA as First Biologic Indicated for Polymyalgia Rheumatica

Kevzara Approved by FDA as First Biologic Indicated for Polymyalgia Rheumatica
GLOBENEWSWIRE
28 Feb 2023
Share Share
Update from Sanofi regarding Kevzara® (sarilumab): Supply constraints anticipated until early 2022

Update from Sanofi regarding Kevzara® (sarilumab): Supply constraints anticipated until early 2022
PRESS RELEASE
13 Oct 2021
Share Share
MSF demands newest COVID-19 treatment recommended by WHO accessible to all

MSF demands newest COVID-19 treatment recommended by WHO accessible to all
EXPRESS PHARMA
27 Sep 2021
Share Share
Tocilizumab and sarilumab cut risk of death in severe COVID-19 patients

Tocilizumab and sarilumab cut risk of death in severe COVID-19 patients
Lucy Parsons PHARMATIMES
08 Jan 2021
Share Share
UK study shows arthritis drugs could improve survival in Covid-19 patients

UK study shows arthritis drugs could improve survival in Covid-19 patients
PHARMACEUTICAL-TECHNOLOGY
08 Jan 2021
Share Share
Two drugs found to reduce mortality in severe COVID-19 patients

Two drugs found to reduce mortality in severe COVID-19 patients
Lucy Parsons PMLIVE
07 Jan 2021
Share Share
Tocilizumab and sarilumab reduce COVID-19 patient mortality by 8.5

Tocilizumab and sarilumab reduce COVID-19 patient mortality by 8.5
Victoria Rees EUROPEANPHARMACEUTICALREVIEW
07 Jan 2021
Share Share
Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy Featured

Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy Featured
BIOSPACE
17 Sep 2020
Share Share
After another Kevzara fail in COVID-19, Sanofi and Regeneron shift their attention elsewhere

After another Kevzara fail in COVID-19, Sanofi and Regeneron shift their attention elsewhere
E.Sagonowsky FIERCE PHARMA
02 Sep 2020
Share Share